The Genomics unit is the latest addition to the Dubai Genetic Center and is due to start offering its services in early 2018. The unit is tasked with providing state-of-the-art genomic services to the community by implementing the latest sequencing technology known as Next-Generation Sequencing. Alongside NGS-based diagnostic services, the unit also provides quantitative PCR (QPCR), classical PCR and Sanger Sequencing as part of its routine molecular genetic testing. The field of Medical Genomics is rapidly progressing and with the current ability to read the entire human DNA (known as genome), it is opening a huge possibility for detailed analysis of the patients’ genetic information and with personalization of health-care. Dubai Genetics Center is one of the few of laboratories in the Middle East that will be providing all in-house genomic services.
Currently, we provide the following services:
- Rare genetic disease diagnosis :
- Using Whole Exome Sequencing (WES) we are able to identify changes in the DNA of patients with rare genetic disorders to help clinician better diagnose their patients and to provide sound genetic counselling services. Most rare genetic diseases have an early onset during childhood, therefore accurate and early prevention using NGS-based diagnostics is key to improve quality of life for the patient and families.
- Cancer diagnosis (Adult and Pediatric) :
We offer targeted-sequencing of large panels of cancer-causing genes to help diagnose patients with cancer. Examples include :
- (1) BRCA1/BRCA2 NGS-based gene panel for identification of familial and inherited Breast and Cervical cancer;
- (2) Acute Myeloid Leukemia NGS panel consistent of 260 genes commonly involved in AML;
- (3) Detailed quantification of BCR/ABL and PML-RARA fusion genes using latest Q-PCR techniques;
- (4) Mutation identification of JAK2 V617F, CARL, KIT, MPL using Sanger sequencing and Allelic-Specific PCR.
- Non-Invasive Prenatal Screening of Trisomy 13, 18, 21 and sex determination (NIPT) :
- We offer non-invasive prenatal testing as part of common genetic screening for trisomies of 13, 18, 21 and sex determination (Male or Female) using fetal cell-free DNA from maternal blood. This is an NGS-based test and NIPT has provided a major advance in antenatal care and screening n counties that has adopted this new genomic technique. We will be able to offer such test as part of prenatal service to pregnant women in week 11-12 of gestation.
General workflow of NGS-based assays